To detect the potential consequences of antibody therapy in APP/PS1 mice at different age, we performed A16 treatment in 3- and 5-month-old APP/PS1 mice before Aβ deposition development in brains, and 10-month-old APP/PS1 mice with significant plaque load, synapse loss and cognitive impairments. This evidence concerns the gene PSEN1 and Cognitive impairment.